Cabaletta Bio, Inc.
Cabaletta Bio, Inc. (CABA): 7 pipeline candidates · 1 upcoming catalyst · ~8 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
8.3 months
D/E 0.43
Lead: Phase 2/Phase 3
7 candidates
1 upcoming, next in ~744d
8 buys · 0 sells (180d)
A transparent, data-derived signal for Cabaletta Bio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$463.1M
Cash
$116.6M
Quarterly Burn
$42.6M
Runway
8.3 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| CABA-201 | Phase 2/Phase 3 |
| caba-201 following preconditioning with fludarabine | Phase 2/Phase 3 |
| DSG3-CAART | Phase 1/Phase 2 |
| MuSK-CAART | Phase 1/Phase 2 |
| rese-cel | Phase 2 |
| rese-cel (resecabtagene autoleucel | — |
| rese-cel (resecabtagene autoleucel) | Phase 1 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
109
Total value held
$174.6M
| Holder | Shares | Value |
|---|---|---|
| jennison associates llc | 8,970,578 | $24.1M |
| adage capital partners gp, l.l.c. | 8,829,758 | $23.8M |
| vanguard capital management llc | 8,057,982 | $21.7M |
| millennium management llc | 5,903,281 | $15.9M |
| woodline partners lp | 2,500,484 | $6.7M |
| two sigma investments, lp | 2,497,917 | $6.7M |
| blackrock, inc. | 2,373,003 | $6.4M |
| marshall wace, llp | 2,179,818 | $5.9M |
| renaissance technologies llc | 2,036,663 | $5.5M |
| qube research & technologies ltd | 1,934,990 | $5.2M |
Showing top 10 of 109 institutional holders of Cabaletta Bio, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Cabaletta Bio, Inc.'s pipeline?
Cabaletta Bio, Inc. (CABA) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Cabaletta Bio, Inc.'s lead drug candidate?
Cabaletta Bio, Inc.'s most advanced tracked candidate is CABA-201 (Phase 2/Phase 3) for Systemic Sclerosis; Relapsing Multiple Sclerosis (RMS); Generalized Myasthenia Gravis (gMG).
What is Cabaletta Bio, Inc.'s next catalyst?
Cabaletta Bio, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimer" — expected July 1, 2028.
What is Cabaletta Bio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Cabaletta Bio, Inc. has approximately 8.3 months of cash runway.
What is Cabaletta Bio, Inc.'s market capitalization?
Cabaletta Bio, Inc.'s market capitalization is approximately $463.1M.
Get the full picture on Cabaletta Bio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.